Stuart Emanuel
Johnson and Johnson Pharmaceutical Research and Development
1000 Route 202
Raritan
NJ 08869
USA
Name/email consistency: high
- The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Emanuel, S., Rugg, C.A., Gruninger, R.H., Lin, R., Fuentes-Pesquera, A., Connolly, P.J., Wetter, S.K., Hollister, B., Kruger, W.W., Napier, C., Jolliffe, L., Middleton, S.A. Cancer Res. (2005)
- A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models. Emanuel, S., Gruninger, R.H., Fuentes-Pesquera, A., Connolly, P.J., Seamon, J.A., Hazel, S., Tominovich, R., Hollister, B., Napier, C., D'Andrea, M.R., Reuman, M., Bignan, G., Tuman, R., Johnson, D., Moffatt, D., Batchelor, M., Foley, A., O'Connell, J., Allen, R., Perry, M., Jolliffe, L., Middleton, S.A. Mol. Pharmacol. (2004)